Cyclizine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Cyclizine: From Nausea and Vomiting to Allergic Urticaria
One-Sentence Summary
Cyclizine is a first-generation H1 receptor antagonist (antihistamine) with anticholinergic properties, classically used for nausea, vomiting, and motion sickness. The TxGNN model predicts it may be effective for Allergic Urticaria, supported by mechanistic plausibility but only 1 indirect literature reference and no registered clinical trials for this specific indication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Nausea, vomiting, and motion sickness (first-generation antihistamine; formal indication data not available in this Evidence Pack) |
| Predicted New Indication | Allergic Urticaria |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L4 |
| Singapore Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Cyclizine is a first-generation piperazine-class H1 receptor antagonist with concurrent anticholinergic activity. By competitively blocking H1 receptors on skin mast cells and blood vessels, it inhibits histamine-mediated vasodilation, increased vascular permeability, and the wheal-and-flare response — the core pathophysiology of urticaria. This is the same mechanism by which all antihistamines treat hives, making the TxGNN prediction pharmacologically coherent.
Allergic urticaria is driven by IgE-mediated mast cell degranulation with histamine release. H1 antagonists are guideline-recommended first-line therapy for this condition. The mechanistic link between Cyclizine and allergic urticaria is therefore not novel — it represents a class effect shared by all H1 antihistamines, and is fully consistent with established pharmacology.
However, there is an important clinical context to consider: international guidelines (EAACI/GA²LEN/EDF/WAO) now strongly prefer second-generation non-sedating H1 antagonists (e.g., cetirizine, loratadine, fexofenadine) as first-line urticaria treatment. Cyclizine's significant central nervous system sedation and anticholinergic burden are well-recognised disadvantages. Unless a specific patient population exists where these properties are beneficial (e.g., urticaria with comorbid nausea), Cyclizine does not offer a competitive clinical advantage over existing antihistamines for this indication.
Clinical Trial Evidence
Currently no related clinical trials registered for Cyclizine in allergic urticaria.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 8573923 | 1995 | Photobiological Mechanistic Study | Dermatology (Basel) | Explores action, inhibition, and augmentation spectra in solar urticaria; demonstrates that light wavelengths outside activating spectra can modulate wheal formation — provides indirect mechanistic context for histamine-mediated urticaria, but does not directly evaluate Cyclizine |
Note: The single retrieved publication addresses solar urticaria (a physical subtype) and does not directly evaluate Cyclizine as a therapeutic agent. Its relevance to allergic urticaria and to Cyclizine specifically is indirect.
Singapore Market Information
Cyclizine holds no product registrations with the Health Sciences Authority (HSA) of Singapore. It is not currently marketed or available as an approved pharmaceutical product in Singapore.
Safety Considerations
Detailed safety data (prescribing warnings, contraindications, and drug interaction records) were not retrieved in this Evidence Pack.
Please refer to the package insert for safety information.
As a first-generation antihistamine with anticholinergic properties, clinicians should be aware of general class-level concerns including CNS sedation, impaired psychomotor function, urinary retention, dry mouth, constipation, blurred vision, and caution in elderly patients and those with glaucoma or prostatic hypertrophy.
Conclusion and Next Steps
Decision: Hold
Rationale: While the pharmacological mechanism connecting Cyclizine (H1 blockade) to allergic urticaria is sound and well-established as a class effect, the evidence base for Cyclizine specifically in allergic urticaria is limited to a single indirect mechanistic study. More importantly, superior second-generation antihistamines already occupy this therapeutic space, leaving little clinical or commercial rationale to pursue Cyclizine as a repurposing candidate for this indication without a clearly differentiated patient subpopulation.
To proceed, the following is needed:
- Identify a differentiated clinical niche: Determine whether any patient subgroup (e.g., urticaria with comorbid severe nausea/vomiting, where Cyclizine's antiemetic properties add unique value) justifies dedicated study over existing second-generation agents
- MOA documentation: Retrieve full mechanism of action data from DrugBank (DB01176) to confirm receptor binding profile and pharmacodynamic properties
- Safety profile clarification: Obtain HSA/regulatory-recognised prescribing information including formal contraindications and drug interaction data
- Head-to-head comparative positioning: If a niche is identified, design a research question that explicitly tests whether Cyclizine's combined antihistamine + antiemetic profile provides meaningful benefit over standard second-generation H1 antagonists in a defined population
- Literature expansion: Conduct a systematic search specifically for Cyclizine in any urticaria subtype (allergic, cholinergic, physical) to confirm absence of direct clinical evidence before investing further resources
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.